Catalyst Funds Management Pty Ltd
Position in ZNTL — Zentalis Pharmaceuticals, Inc.
CIK 1896150
SYDNEY NSW, C3
Position in ZNTL
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$39,078
-$38,536 QoQ
Shares Held
16,700
-67.5% QoQ
Ownership
0.023%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ZNTL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Catalyst Funds Management Pty Ltd holds $22,504,759 across 58 Biotechnology names. ZNTL ranks #47 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
66,261 | $6,443,882 | |
| 2 | RPRX |
Royalty Pharma plc
|
79,147 | $3,796,681 | |
| 3 | MRNA |
Moderna, Inc.
|
55,363 | $2,812,440 | |
| 4 | PTCT |
Ptc Therapeutics, Inc.
|
11,200 | $763,056 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
25,031 | $693,358 | |
| 6 | QNCX |
Quince Therapeutics, Inc.
|
30,000 | $606,000 | |
| 7 | ABVX |
Abivax S.A.
|
5,000 | $556,750 | |
| 8 | NKTR |
Nektar Therapeutics
|
6,700 | $482,065 |
All Filings in ZNTL
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $39,078 | 16,700 | Shares | Sole | 2026-05-11 | |
| 2025-09-30 | $77,614 | 51,400 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $31,088 | 26,800 | Shares | Sole | 2025-08-12 | |
| 2024-06-30 | $14,315 | 3,500 | Shares | Sole | 2024-12-18 | |
| 2024-03-31 | $146,568 | 9,300 | Shares | Sole | 2024-12-05 | |
| No filing history on record for this holder in this stock. | ||||||